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1.  Summary 
 
Title: Perinatal Outcome in Pregnancies with Gestational Diabetes 
Name and Surname: ATOUI Yasmine 
 
                    The aim of this graduate thesis was to explore the perinatal outcome of 
gestational diabetes mellitus in our referral center in Zagreb. 
All over the world, physicians are faced with many challenges when it comes to diabetes, 
metabolic syndromes or other endocrinological disturbances.  
Modern lifestyles, especially western diets create a favorable background for the emergence 
of this type of conditions. This environmental factor coupled with genetic predispositions 
results in an increased interest for GDM as it is a partially a preventable disease. 
In our study, we used a database of 2362 pregnant women suffering from this condition. 
We found that these women had a statistically higher prevalence of hypertension before and 
throughout the pregnancy. This risk factor led to a higher number of operative delivery (C-
sections). 
Newborns also presented with a higher proportion of macrosomia than in the general 
population. This feature; in addition to the serious neonatal complications such as 
hyperbilirubinemia, hypoglycemia and respiratory disturbances, justifies the use of c-sections 
as a mode of delivery. 
Our results emphasize the importance of proper follow up of women in pregnancy; starting 
from early screening to appropriate management using modern imaging techniques and 
adequate nutritional approach. 
 
 
 
 
Key words: gestational diabetes mellitus, hypertension, macrosomia, neonatal complications, 
operative deliver
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2. Preface 
 
Definition and epidemiology 
Gestational Diabetes Mellitus (GDM) is defined as the state of carbohydrate 
intolerance that has its onset or first recognition during pregnancy. It affects up to 
15% of pregnancies worldwide.1  Because GDM is such a heterogeneous entity, 
estimates of occurrence vary with ethnic diversity of the populations under study, 
geographic area, screening frequency, and diagnostic criteria. 
In Croatia, it is present in 5% to 15% of pregnancies according to the new criteria 
established by the Hyperglycemia and Adverse Pregnancy Outcome (HAPO) study. 
 
Endocrinological changes 
Pregnancy, due to many endocrinological changes, is a physiological pro-
diabetogenic state. 
The associated insulin resistance emerges in the 2nd trimester and is more prominent 
in the late 3rd trimester, while in the 1st trimester a slight increase in the insulin 
sensitivity has been observed. 2 
This increase in insulin resistance results in increase in maternal and fetal glucose, 
free fatty acids (FFA) and amino acids. These changes are essential for the 
regulation of energy metabolism and fetal growth. 
Interestingly enough, in normal pregnancies, the insulin sensitivity is decreased by 
30% to 60% compared to healthy non pregnant women.2 
In both GDM and in pregnancies with NT (normal tolerance to glucose) an increase 
of the hepatic glucose production of 30% has been observed.3 This happens despite 
an increased fasting plasma insulin in GDM compared to pregnancies with NT, and 
confirms the existence of a hepatic insulin resistance. 
Biopsy samples taken during cesarean sections demonstrated a decreased GLUT-4 
transporter concentrations in adipocytes but not in the muscles of women with GDM4. 
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Knowing that muscles are responsible for 80% of total insulin-dependent glucose 
uptake, one can conclude that this defect does not cause the insulin resistance. 
Focus has then shifted towards the study of the post-receptor level.  
In human skeletal muscle, impaired insulin receptor autophosphorylation was found. 
More precisely; obese women with GDM showed a decrease in tyrosine 
phosphorylation of the insulin receptor β-subunit. 
Also; the impaired suppression of FFA by insulin in GDM has been related to a 
decrease in the tissue IRS-1 protein level and an increase in p85α subunit of PI-3K in 
adipocytes. 
 
The pathogenesis of the metabolic changes in GDM is still unclear, but the study of 
hormonal changes seems to explain the impaired glucose and lipid homeostasis. 
The hormones relevant to our study are the following: hPL, progesterone, estrogen 
and Prolactin. 
Human Placental Lactogen (hPL) is a protein hormone produced by the placenta. It 
antagonizes the effects of insulin which would normally inhibit the lipolysis 
(breakdown of triglycerides into FFA in the adipocytes) and also uses the excess 
glucose in the liver to synthetize FFA. The latter would then be transported as 
lipoproteins back to the adipocytes in order to form triglycerides. This means that 
insulin has an anabolic effect in adipose tissue. 
On the contrary, under the influence of hPL, one can observe an increase in the 
lipolysis and therefore an increase as well in the FFA concentration in the plasma. 
 In combination with the maternal hyperinsulinemia, hPL increases the protein 
synthesis, which provides a source of energy for the fetus. 
And finally, it is worth mentioning that the increase in hPL level parallels the 
development of the insulin resistance. 
The second hormone we will consider is Progesterone. 
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Progesterone, is a steroid hormone also secreted by the placenta. In fasting women 
with NT, progesterone increases the insulin concentration without leading to a 
hypoglycemia, thereby indicating a resistance to insulin. 
This resistance is then observed even in the context of an absence of glucose 
intolerance. 
The third hormone we will consider is Estrogen. 
Estrogens activity is based on hepatocyte stimulation to increase the concentration 
on cortisol-binding globulin. The adrenal cortisol production is then raised to maintain 
free cortisol levels. Although glucocorticoids antagonize insulin action, no direct 
connection has been established between free cortisol levels and insulin resistance. 
The last hormone that was documented is Prolactin. Also known as luteotropic 
hormone or luteotropin; it is a peptide produced by the pituitary gland. 
So far, its increase doesn’t seem to have an influence either. 
The role of adipocytokines and cytokines has also been investigated. 
TNF α seems to be a better indicator of insulin resistance than placental hormones 
and cortisol5. 
The increase in TNF α levels parallels the increase in insulin resistance. In addition; it 
induces leptin expression, which has been associated with chronic hyperinsulinemia 
in the late second trimester of pregnancy. 
The plasmatic leptin concentrations correlate with the glycemic control, the insulin 
resistance, the body weight and the overall maternal weight gain during pregnancy. 
Therefore; leptin at the entry of the prenatal care could be an important predictor of 
the expected postpartum weight reduction. 
Adiponectin on the other hand, suppresses the TNFα activity, and increases the 
hepatic glucogenosis and insulin sensitivity. 
In several cases of insulin resistance, hypoadiponectinemia was documented.2 
In women with GDM, adiponectin mRNA levels were decreased (in biopsy samples 
taken from abdominal subcutaneous tissue). Although it was present in cord blood, 
levels were slightly lower than in offspring of healthy women6. 
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Finally the last adipocyte secreted hormone that is investigated is resistin. This 
peptidic hormone, in mice model, seems to cause a decrease in insulin sensitivity. Its 
precise role during normal and diabetic pregnancies is still not clear7. 
 
 
Risk Factors 
Several anamnestic risk factors have been identified. They include a previous history 
of GDM, recurrent spontaneous abortions, unexplained intrauterine fetal death, 
previous infant with major congenital anomalies, previous macrosomic infant, 
recurrent preeclampsia, recurrent candidiasis, family history of DM in first-degree 
relatives and history of polyuria, polydipsia or glycosuria. 
Other risk factors are well known such as maternal age over 30 years, excessive 
weight gain during pregnancy (weight>18kg), maternal obesity (BMI>27kg/m2 or 
pregnancy weight) and development of polyhydramnios and/or fetal macrosomia in 
present pregnancy. 
Diagnosis 
The most common diagnostic test recommended for GDM is the 2 hour oral glucose 
tolerance test (OGTT). 
It is conducted with a 75mg glucose load that the patient drinks within 5minutes after 
a fasting sample is drawn. 
Glucose level is then measured at 1, and 2 hours. 
 The thresholds recommended by the HAPO study represent odds ratios of 1.75, and 
are fasting plasma glucose 92 mg/dl (5.1 mmol/L), 1-hour 180 mg/dl (10 mmol/L), 
and 2 hours 153 mg/dl (8.5 mmol/L).8 
The test is considered positive if one values is abnormal. 
Current treatment 
Treatment revolves around good glycemic control as it will be discussed later on. 
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During the second trimester of pregnancy, the need for insulin is higher and 
complications due to hypertension can be controlled pharmacologically by using 
methyldopa or nifedipine as a chronic therapy. 
 
Problems encountered during pregnancy 
For most women, GDM does not cause noticeable signs or symptoms. 
Our main concern is to prevent maternal and neonatal complications which will be 
further discussed. These include perinatal mortality and congenital malformations but 
also increased maternal morbidity and mortality. 
 
 
 
3. Hypothesis 
 
Women with GDM have adverse perinatal outcome in relation to healthy pregnant 
women. 
 
 
 
4. Objectives 
 
 
The focus of this graduate thesis was to explore the perinatal outcome in 
pregnancies with GDM from the maternal and neonatal perspectives. 
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5. Material and Methods 
 
 
The study included database of 4195 singleton pregnancies. Of all, there were 2362 
women with gestational diabetes mellitus according to WHO criteria (based on HAPO 
study recommendations). All women with gestational diabetes mellitus were treated 
with diet, and the inclusion of insulin in therapy was exclusion criteria for study. The 
patients gave birth at University Hospital Centre Zagreb (UHC Zagreb), Department 
of Obstetrics and Gynecology. The ethical committee of UHC Zagreb gave approval 
for the use of data.  
Numerical data were described by the mean value (arithmetic mean) and standard 
deviation in the case of normal distributions. In other cases, data were described by 
the median and the boundaries of interquartile range. Distribution normality of 
numerical variables was tested by the Shapiro-Wilk test. Student t test was used for 
analysis of normally distributed numerical variables and Mann-Whitney U test was 
used for analysis in the cases of deviation from normal distribution. Connection of 
normally distributed numerical variables was evaluated by the Pearson correlation 
coefficient r, and in the cases of deviation of normal distribution by the Spearman 
correlation coefficient ρ. Level of significance was set as α=0,05. All of the data were 
statistically analysed by the program MedCalc Statistical Software version 13.1.2 
(MedCalc Software bvba, Ostend, Belgium;  http://www.medcalc.org;  2014). 
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6. Results 
 
We found slight age difference between the two groups of patients. The pregnancy 
weight gain was greater in control group, whereas pregestational BMI was greater in 
GDM group. This is an encouraging result, meaning that patients with GDM were 
strictly controlled for weight gain since they are a high risk population. 
 
Table 1. Age and weight of patients 
 
Group   
Control GDM 
Z P 
Mean (SD) Mean (SD) 
Age (years) 30,1 (5,4) 31,8 (5,4) -9,855 < 0,001 
Pregnancy weight gain (kg) 14,8 (5,6) 12,9 (6,3) 10,229 < 0,001 
Pregestational BMI (kg / m 2) 23,9 (4,4) 26,1 (7,1) -11,274 < 0,001 
BMI – Body Mass Index; Z-Mann-Whitney U test value; P-probability 
 
 
 
The prepregnancy hypertension was more frequent in the group of GDM patients, 
being 5 times greater than in the control group. 
 
 
Table 2. The frequency of preexisting hypertension 
 
Preexisting hypertension 
Total 
No Yes 
Group 
Control N (%) 1820 (99,3) 12 (0,7) 1832 (43,7) 
GDM N (%) 2279 (96,6) 79 (3,4) 2358 (56,3) 
Total N (%) 4099 (97,8) 91 (2,2) 4190 (100) 
χ2 = 35,251; P < 0,001. 
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Women with gestational diabetes more frequently had hypertension during 
pregnancy as well. Of all women with hypertensive disorder, 73 in GDM group had 
preeclampsia.  
 
 
Table 3. Hypertension during pregnancy 
 
Hypertension during pregnancy 
Total 
No Yes 
Group  
Control N (%) 1743 (95,1) 89 (4,9) 1832 (43,8) 
GDM N (%) 1997 (85) 355 (15) 2352 (56,2) 
Total N (%) 3740 34 4184 (100) 
χ2 = 120,074; P < 0,001. 
 
 
The rate of preterm delivery was greater in the group of women with gestational 
diabetes. 
 
Table 4. Preterm delivery frequency 
 
Pregnancy outcome 
Total 
Miscarriage 
Preterm 
delivery* 
Term 
delivery 
Group 
Control 
N 
(%) 
55 (3,0) 156 (8,5) 1622 (88,5) 
1833 
(43,7) 
GDM 
N 
(%) 
12 (0,5) 309 (13,1) 2041 (86,4) 
2362 
(56,3) 
Total 
N 
(%) 
67 (1,6) 465 (11,1) 3663 (87,3) 4195 (100) 
χ2 = 60,115; P < 0,001. 
*Post hoc: χ 2 = 21,684; P < 0,001. 
 
 
The rate of cesarean section was greater in group of women with gestational 
diabetes. The rate in control group was 18,1% and was similar to the state average 
rate of cesarean section. The rate was 35,2% in GDM group, as shown in table 5. 
 
 
Table 5. Operative delivery 
 
Pregnancy termination 
Total 
Vaginal SC 
Group 
Control N (%) 1490 (81,9) 330 (18,1) 1820 (43,5) 
GDM N (%) 1530 (64,8) 831 (35,2) 2361 (56,5) 
Total N (%) 3020 (72,2) 1161 (27,8) 4181 (100) 
χ2 = 149,219; P < 0,001. 
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The rate of newborns large for gestational age (i.e. > 90 percentile) was greater in 
group of women with gestational diabetes. There was no difference for small for 
gestational age newborns 
 
Table 6. Newborn growth in relation to GDM 
 
Growth percentile 
Total 
<10 10-90 >90* 
Group 
Control N (%) 96  (5,4) 1399 (79,0) 277 (15,6) 1772 (44,5) 
GDM N (%) 148 (6,7) 1540 (69,7) 521 (23,6) 2209 (55,5) 
Total N (%) 244 (6,1) 2939 (73,8) 798 (20,0) 3981 (100) 
χ2 = 45,025; P < 0,001. 
*Post hoc: χ 2 = 38,775; P < 0,001. 
 
 
 
The incidence of fetal macrosomia differed between newborns. The GDM group of 
women had macrosomic infant more often. 
 
Table 7. Frequency of macrosomia 
 
Macrosomia 
Total 
Yes* No Hypotrophic 
Group 
Control N (%) 311 (17,6) 1366 (77,1) 95 (5,4) 1772 (43,2) 
GDM N (%) 479 (20,5) 1703 (73,0) 151 (6,5) 2333 (56,8) 
Total N (%) 790 (19,2) 3069 (74,8) 246 (6,0) 4105 () 
χ2 = 8,980; P = 0,011. 
*Post hoc: χ2 = 5,264; P = 0,022. 
 
 
Most frequent neonatal complications included hyperbilirubinemia, hypoglycemia, 
infection, Cushingoid appearance and transitory respiratory disturbance. The group 
of mothers with gestational diabetes during pregnancy had more often infants with 
some of abovementioned complications. There was no significant difference for rare 
complications such as hip dysplasia, clavicle fracture or cephalhematoma.  
 
Table 8. Frequency of neonatal complications 
 
Neonatal complications 
Total 
No Yes 
Group 
Control N (%) 1723 (94,7) 97 (5,3) 1820 (43,5) 
GDM N (%) 2060 (87,3) 301 (12,7) 2361 (56,5) 
Total N (%) 3783 (90,5) 398 (9,5) 4181 (100) 
χ2 = 64,822; P < 0,001. 
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Of all children 98,3% had no congenital malformation. The group of mothers with 
GDM had more than two folds greater frequency of congenital malformations, mostly 
cardiac. 
 
Table 9. Frequency of congenital malformations 
 
Congenital anomalies 
Total 
No Yes 
Group 
Control N (%) 1804 (99,1) 16 (0,9) 1820 (43,5) 
GDM N (%) 2307 (97,7) 54 (2,3) 2361 (56,5) 
Total N (%) 4111 (98,3) 70 (1,7) 4181 (100) 
χ2 = 11,537; P = 0,053. 
 
 
 
There was statistically but not clinically significance in gestation at birth between two 
groups. Mothers with GDM had newborns with greater newborns weight. Apgar 
scores in first and fifth minute were clinically non-significant.  
We found significant correlation between maternal weight gain during pregnancy and 
newborns weight (r = 0,459; P < 0,001). As mothers had greater weight gain during 
pregnancy newborns weight was greater. 
Table 10. Birth weight and Apgar score in relation to GDM 
 
 
Group   
Control GDM 
Z P 
Mean (SD) Mean (SD) 
Gestation (weeks) 39 (4) 39 (2) -2,457 < 0,001 
Newborn's weight (grams) 3338,8 (797,3) 3450,0 (707,0) -4,773 < 0,001 
Apgar score 1st min. 10 (1) 9 (1) 5,081 < 0,001 
Apgar score 5th min. 10 (1) 10 (3) 0,258 0,797 
BMI – Body Mass Index; Z-Mann-Whitney U test value; P-probability 
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7. Discussion  
 
Table 3 showed us the prevalence of hypertension in women suffering from GDM. 
This pregnancy induced hypertension when associated with proteinuria is defined as 
a clinical entity called preeclampsia. 
 
In the literature it is mentioned that this pathology occurs in 20% of diabetic pregnant 
women, which is 3 times more frequently than in healthy pregnant women and 
significantly increases perinatal mortality and morbidity.9, 10. 
According to the data of the Obstetrics and Gynecology Clinic in Zagreb, the 
perinatal mortality of diabetic pregnant women with pre-eclampsia in a period of 40 
years is high and amounts to 20,6% in relation to 3,5 of normotensive diabetic 
pregnant women 
It seems appropriate at this point to mention the other relevant conditions that women 
with GDM might encounter during their pregnancy such as infections or DKA. 
 
Infections are significantly more frequent in diabetic pregnant women than in healthy 
ones. 
Pyelonephritis can be expected in 4% of diabetic women, and in only 1% of pregnant 
women in the non-diabetic population. 
Significant bacteriuria is also frequent and amount to about 40% in pregnancies with 
diabetes 11, 12. 
It is interesting to note that hypertension is also more frequently observed in pregnant 
women with bacteriuria than in those with sterile urine. 13 
 
 
Diabetic ketoacidosis (DKA) is a rare (less than 1% of cases) but a serious 
complication. 
    
 
12 
 
Bearing in mind the development of insulin resistance during pregnancy, lipolysis and 
ketogenesis also increase and therefore DKA can occur even with minimal 
hyperglycemia. 
DKA is accompanied by a high fetal loss, which amounts to 20%. It should be treated 
quickly, in a similar manner than in non-pregnant patients. 13 
 
Now that we have analysed the maternal complication that women encounter, the 
next logical step is to observe the type of delivery that is chosen. 
 
As shown in table 5, women with GDM tend to have a higher rate of cesarean 
sections. 
 
A recent study showed that GDM significantly increased the risk of 
emergency cesarean delivery (adjusted odds ratio 1.9, 95% confidence interval 1.03-
3.5, p = 0.039) only among nulliparous women, adjusted for age, body mass index, 
and gestational weight gain14; 
When considering elective C-section, in patient with type 1 diabetes, they should be 
performed on a morning list to enable the patient to return to oral intake and normal 
insulin regimen by the following morning. 
Prophylactic antibiotics should be administered in both cases15 and DVT prophylaxis 
should as well be given to obese women. 
 
As shown in table 7, the most characteristic feature of the newborns is macrosomia. 
 
This condition is a frequent complication in pregnancies of women with diabetes. The 
exact incidence depends on the definition used. It is often defined by a birth weight 
>4000g or greater than 90% for the gestational age. 
Macrosomia potentially affects up to 10% of pregnancies and has been reported in 
20-25% of the infants in women with diabetes and in 7-10% of them when using a 
cut-off value of 4500g. 16, 17 
The most dangerous condition related to macrosomia is shoulder dystocia. 
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The incidence of shoulder dystocia increases with the birth weight and is affected by 
maternal diabetes as well. 
Langer et al, reported a 21,8% incidence of shoulder dystocia in diabetic women 
delivering infants weighting more than 4500g compared to 7,5% in non-diabetics.20 
Estimation of the birth weight are based on the parietal diameter, the head 
circumference, the abdomen circumference and the femur length. 
 
  
 
 
Many neonatal complications have been documented in the literature.  
Among all these complications, respiratory distress is the most serious complication 
for the neonate. Fetuses affected by GDM are at elevated risk (perhaps 5- to 6-fold 
greater) of lung immaturity compared with age-matched controls. [Oxygen 
supplementation, ventilatory support, and surfactant replacement are among the 
treatments available, and care may require consultation with a neonatologist.18 
 
Amniocentesis is also performed to assess the fetal maturity. The lecithin-
sphingomyelin L/S ratio being not significantly different from the one in healthy 
women, phosphate-diglycerol seems to be a more reliable parameter in estimating 
neonatal respiratory distress. 
 
 
Hypoglycemia, which is one of the most obvious complications, results from fetal 
hyperinsulinemia, and should be treated and monitored every hour until stabilization. 
Finally, polycythemia is a result of chronic intrauterine hypoxemia and placental 
insufficiency secondary to poor glycemic control. Hypoxemia causes increased fetal 
erythropoietin release and subsequent polycythemia. When these erythrocytes break 
down, there is increased incidence of hyperbilirubinemia at days to weeks after 
birth.19 
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Long-term effects include an increased incidence of childhood obesity, early 
adulthood type 2 diabetes mellitus, and intellectual-motor impairment. 
 
 
Neonates born to women with GDM also present with a higher prevalence of 
congenital malformations as we showed in table 9. 
 
 
Progresses in modern medicine have enabled us to monitor the growth of the fetus 
thanks to ultrasound technique and consequently to detect these malformations. 
A detailed ultrasound examination should be performed between 18 and 20 weeks to 
detect possible abnormal development of spine, head, kidney and heart. 
During the last trimester, from the 34th or the 36th weeks of pregnancy, the need for 
insulin decreases physiologically, as more glucose is transferred to the fetus. 
Therefore more frequent ultrasound examinations are required to monitor the fetal 
growth and measure the quantity of the amniotic fluid. 
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8. Conclusion 
 
The most valuable tool that physicians can use besides prevention and adequate 
screening is appropriate glycemic control. 
 
Our main goal is to maintain optimal glycemic concentration.  This is why pregnancy 
is not recommended before obtaining an HbA1c value <7%. 
Ideal fasting blood glucose values in pregnancy are between 3,6mmol/L and 
3,8mmol/L, and postprandial blood glucose less than 7,0mmol/L. 
Women with GDM should be encouraged to self-care through a healthy diet and 
physical activity and self-monitoring. 
A simple diet individually adjusted is also recommended. Supplementation with folic 
acid (5mg/day) should continue until the 12th week of pregnancy. 
The necessary energy intake is about 25-30kcal/kg of the ideal body weight, divided 
into six daily meals and it consists of 55% of carbohydrates, 20% of proteins and 
25% of fat. 
Blood glucose monitoring is crucial as well. 
Measures should be taken before breakfast, 2h after breakfast, before lunch, 2h after 
lunch, before dinner, 2h after dinner, before bedtime and at about 3am. 
Treatment with insulin can also introduced. 
When this therapeutic option is chosen; intensive conventional insulin treatment is 
done as follows: 
The patient can take long acting insulin in the evening before going to bed, or 2 
injections of medium acting insulin every 12h to maintain a basal level. Before meals, 
injections of short acting insulin can be taken. 
Insulin pumps are more frequently used since they deliver continuous insulin 
injection. 
Regulation of the glycemia should be done every 2 weeks, and self-monitoring daily. 
GDM is therefore a condition that requires a multidisciplinary approach, involving the 
obstetrician of course; but also nutritionists, endocrinologists and neonatologists.  
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Only through this surveillance and patient education and awareness, we can hope to 
decrease the chances of these women and their newborns to develop diabetes 
mellitus and its systemic complications later in life. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
17 
 
 
9. Acknowledgements 
 
I would like to thank my mentor Josip Juras for the quality of his time, his availability 
and kindness. 
 
 
I also thank my family for their constant love and support. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    
 
18 
 
10. References  
 
1.  http://www.idf.org/gestational-diabetes 
2.  Alexandra Kautzky-Willer, Dagmar Bancher-Todesca, 2005, Endocrine 
changes in diabetic pregnancy, Djelmiš J, Desoye G, Ivanišević M, Diabetology of 
Pregnancy, Basel, Karger. 
3.  Amini SB, Calles J, Catalano PM, Roman NM, Sims EAH, Tyzbir ED, Wolfe 
RR,   1993, Carbohydrate metabolism during pregnancy in control subjects and 
women with gestational diabetes, Am J Physiol; 264: E60-E67  
4.  Baron A, Garvey WT, Golichowski AM, Hancock JA, Maianu L, 1992, Gene 
expression of GLUT4 in skeletal muscle from insulin-resistant patients with 
obesity, IGT, GDM, NIDDM, Diabetes; 41: 465-475 
5.  Catalano PM, Challier JC, Friedman JE, Hauguel- de Mouzon S, Huston-
Presley L, Kalhan SC, Kirwan JP, Lepercq J, 2002, TNF α is a predictor of insulin 
resistance in human pregnancy, Diabetes; 51: 2207-3313. 
6.  Calder AA, Hamilton BA, Havel PJ, Johnstone FD, Lindsay RS, Scottish 
Multicenter Study of Diabetes Pregnancy, Walker JD, 2003, Adiponectin is 
present in cord blood but is unrelated to birth weight, Diabetes Care; 26: 2244-
2249. 
7.  Ahima RS, Bailey SC, Banerjee RR, Bhat S, Brown EJ, Lazar MA, Patel HR, 
Steppan CM, Wright CM, 2001, The hormone resistin links obesity to diabetes, 
Nature; 409: 307-312. 
8.  Coustan DR, Dyer AR, Lowe LP, Metzger BE, 2010, The HAPO Study: Paving 
The Way For New Diagnostic Criteria For GDM, Am J Obstet Gynecol; 202(6): 
654.e1-654.e6. 
9.  Cousins L, 1987, Pregnancy complications among diabetic women, Obstet 
Gynecol Surv; 42:140-149. 
10.  D’Alton ME, Dudley DK, Garner PR, Hardie M, Huard P, 1990,  Pre-
eclampsia in diabetic pregnancies, Am J Obstet Gynecol; 163:505-508. 
    
 
19 
 
11.  Blajic J, Djelmiš J, Drazancic A, Kuvacic I, Latin V, 1997, Bacteriuria in 
diabetic pregnancies, Diabetol Croat; 26:175-181. 
12.  Cousins L, 1988, Obstetric complications, Coustan DR, Diabetes Mellitus in 
pregnancy; pp455-468, New York, Churchill Livingstone. 
13.  Djelmiš J, 2005, Clinical management of pregnancies complicated with type 
1/type 2 diabetes mellitus, Djelmiš J, Desoye G, Ivanišević M, Diabetology of 
pregnancy, Basel, Karger. 
14.  Boriboonhirunsarn D, Waiyanikorn R, 2016, Emergency cesarean section 
rate between women with gestational diabetes and normal pregnant women, 
Taiwan J Obstet Gynecol; 55(1):64-7. 
15.  Hofmeyr GJ, Smaill F, 2004, Antibiotic prophylaxis for cesarean section; The 
Cochrane library, issue 1. 
16.  Giampietro O, Gregory O, Miecolli R, Navalesi R, Penno O, Tallarigo L, 1986, 
Relation of glucose tolerance to complications of pregnancy in nondiabetic 
women, N Engl J Med; 315:989-992. 
17.  Anyaegbunam A, Brustman L, Divon M, Langer O, Levy J, Merkatz R, 1989, 
Glycemic control in gestational diabetes- How tight is tight enough: Small for 
gestational age versus large for gestational age?, Am J Obstet Gynecol; 61:646-
653. 
18.  Hubbell JP , Nel RK, Robert MD, et al, 1976, Association between maternal 
diabetes and the respiratory distress syndrome in the newborn, N Engl J 
Med.;294:537-560. 
19.  Clemons GK ,Teramo KA,  Widness JA,  et al, 1990,  Direct relationship of 
antepartum glucose control and fetal erythropoietin in human type I (insulin-
dependent) diabetic pregnancy, Diabetologia.;33:378-383. 
20.  Aarons JH, Jovanovic-Peterson L, Knopp RH, Metzger BE, Mills JL, Peterson 
CM, Reed GF, 1991, Maternal postprandial glucose levels and infant weight: The 
diabetes in early pregnancy study, Am J Obstet Gynecol; 164:103-111. 
 
    
 
20 
 
11. Biography 
 
Yasmine Yakouta Atoui was born in Algeria in 1989. 
After graduating from high school in Toulouse (France), she completed a Bachelor in 
Life Sciences in 2010 in the Faculty Pierre et Marie Curie in Paris. 
She then moved to Zagreb to enroll in the University of Medicine in the English 
program. 
After obtaining her diploma, she plans to apply for the internship in Zagreb and take 
the national licensing examination. 
Besides medicine, she is interested in literature, traveling, dance and languages. 
 
 
 
 
 
 
